SYNTOPIA is developing innovative tools enabling the pharmaceutical industry and CROs to use patients' primary cells on a large-scale in their in vitro cell-based assays.
Our techbio platform combines high-throughput phenotypic screening on a microfluidic chip and in silico models to predict the evolution of key parameters of a biological system (100 times more) from a minimum of experiments (10 times less), paving the way for a faster and less costly understanding of biological systems.
SYNTOPIA is a Parisian startup and a spin-off from the Laboratory of Biophysics and Evolution at ESPCI-PSL University. Our development is supported by prestigious national and European programs and its core technology is protected by two patents.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 6, Rue Jean Calvin, Institut Pierre-Gilles De Gennes,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Phenotypic analysis, High-Throughput Screening, High-Content Screening, Microfluidic, Deep Learning Neural Network, Rare Diseases, Oncology, 3D cell models, Life Cycle Management, Drug Discovery.
- HQ
- Paris, Île-de-France
Syntopia Questions
Syntopia's LinkedIn profile is https://fr.linkedin.com/company/syntopia-bio
Syntopia has
2 employees.
View email and phone details for 2
employees at Syntopia.
Syntopia's industry is
Biotechnology Research
Syntopia's top competitors are
Oria Bioscience,
Owlo,
Cgenetix,
Celeos Sas,
Plantibodies,
Brink Therapeutics,
Algenscribe Sas,
Biohive,
Sensebiotek Health Care,
Byorna.
Syntopia's categories are Biotechnology Research
Syntopia's founding year is 2024
